Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by KayakerBCon Apr 03, 2018 12:27pm
161 Views
Post# 27821437

RE:RE:RE:RE:Independent view on Bioasis Tech

RE:RE:RE:RE:Independent view on Bioasis Tech ....However, this does not resolve the issue of superiority of xB3 vs. another BBB crossing technology for % delivery of payload or ability to cross the BBB....

I don't see an issue.  You don't need your dream study to have a high level of confidence that XB3 transports higher payload percentages than other companies have achieved.  I'm pretty confident they all design their studies with payloads, time courses, and imaging analysis to demonstrate the highest percentages possible.  And yet, I don't think we've ever seen any of them achieve the payload percentages of XB3.

And, as discussed here many times, you know it's more complicated than just payload percentages.  What about transferrin and insulin receptors in the rest of the body and the resulting uptake issues outside the BBB?





Bullboard Posts